Ignacio Hernández Medrano (Madrid, Spain)
(PLNS) Artificial intelligence and medicine: The secrets for a good marriage
Neurologist at the Ramón y Cajal Hospital, Nacho Medrano was considered by the specialised press among the most influential people in health in 2016, for his work promoting systemic changes in the sector through information technologies and big data. His curriculum includes several masters in health management, as well as a step by the Strategic Management of the Ramón y Cajal Institute of Health Research. After graduating in 2014 from Singularity University (NASA, Silicon Valley), he founded two emerging companies in artificial intelligence in healthcare: Savana (electronic medical record processing) and Mendelian (diagnosis and treatment of rare diseases). In 2018 he was chosen as the digital personality in Salud del año.
Eli Sprecher (Tel Aviv, Israel)
(PL-A01) Combing through the genetics of hair disorders
Eli Sprecher received his MD and PhD degrees from the Hebrew University of Jerusalem and specialized in dermatology at the Rambam Medical Center, Haifa. He spent a post-doctoral fellowship at Thomas Jefferson University, Philadelphia, and served as attending physician at the Rambam Medical Center until 2008. During this period he was Deputy Director for Academic affairs at the Rappaport Institute for Research at the Technion-Israel Institute of Technology, and founded as well as directed the Center for Translational Genetics at the same institution. He became Chair of the Department of Dermatology at the Tel Aviv Medical center in 2008, Professor of Dermatology at the Sackler Faculty of Medicine, Tel Aviv University in 2010, where he also received the Frederick Reiss chair of Dermatology in 2014. He also serves as Deputy Director General for Research and Development. He was named visiting professor of Dermatology at the Lee Kong Chian School of Medicine, Singapore, in 2018. He has co-authored over 300 scientific publications, has mentored over 40 students and has received numerous national and international prizes and honors.
His research focuses on the genetic basis of skin diseases. His group aims at understanding the molecular genetics of both simple and complex traits, deciphering their pathogenesis and then attempting at translating this new knowledge into innovative therapeutic tools.
Georg Stingl (Vienna, Austria)
(PL-A02) How the dermatologist can influence the availability of new treatments
Georg Stingl is professor emeritus at the Department of Dermatology, Medical University of Vienna, Austria.
Prof. Stingl earned his MD from the University of Vienna Medical School in 1973. After his internship and residency training at the Department of Dermatology of Vienna’s University Medical School, he worked as a postdoctoral fellow at the Dermatology Branch of the National Cancer Institute (1977-1978) and as a guest scientist at the Laboratory of Immunology, National Institute of Allergy and Infectious Diseases (1985-1986) of the National Institutes of Health, Bethesda, MD, USA. From 1978-1981 he served as Faculty member of the Department of Dermatology of Innsbruck’s University Medical School and then moved to Vienna where he ultimately became Professor and Chairman of the Department of Dermatology at the Medical University.
Prof. Stingl’s major scientific accomplishments include the discovery of Langerhans cells as immunocytes and their role as targets of physicochemical agents, drugs and HIV; the first identification of the indigenous T cell population of rodent skin; the detection of anti-FcεR1 autoantibodies in the sera of patients with chronic urticaria; the use of genetically modified melanoma cells as vaccines for patients with far advanced disease; the induction of lytic molecules on dendritic cells after stimulation with TLR 7/8 ligands. In addition, he conducted many clinical trials investigating safety and efficacy of different immunomodulatory compounds.
His work is documented in more than 250 original publications, 200 reviews and book chapters as well as four books. Over the years, Prof. Stingl has appeared as Guest Professor at several medical universities and as invited speaker at many symposia and conferences. He is member of the Board of several scientific societies and organisations, advisory panels, scientific journals and committees.
During his career he has received several prestigious awards such as the William Montagna Award and the Stephen Rothman Award of the Society for Investigative Dermatology and the Lifetime Achievement Award of the American Skin Association. In 1999, he received the Honorary Doctorate from the Semmelweis Medical University in Budapest and the Silver Decoration of Honour for Services to the Republic of Austria in Vienna. He is Honorary Member of the Society for Investigative Dermatology, the European Society for Dermatological Research and The Japanese Society for Investigative Dermatology. He is also Member of the Austrian and the German Academy of Sciences as well as Foreign Associate of the US National Academy of Medicine.
Bernard Cribier (Strasbourg, France)
(PL-B01) Rosacea: From the new spectrum to the new therapies
Bernard Cribier is the Head of Department of Dermatology & Dermatopathology at the Strasbourg University Hospital, France. He is a certified Dermatologist since 1989 and has a PhD in Virology. His main fields of interest are dermatopathology, rosacea and history of dermatology.
He is the Editor-in-Chief of the Annales de Dermatologie et de Vénéréologie since 2010. He is the author of 438 indexed articles (H index: 59) and 72 book chapters, including a book dedicated to clinicopathological correlation: “Dermatologie, de la Microscopie à la Clinique”. In the field of dermatopathology, he is the coordinator of the French network for adnexal carcinomas (CARADERM). All his academic efforts are dedicated to teaching dermatopathology to both dermatologists and pathologists and to emphasize the critical role of dermatopathology in dermatology.Bernard Cribier is also a member of the international ROSCO group which contributed significantly to the recent classification of rosacea.
Stephan Lautenschlager (Zürich, Switzerland)
(PL-B02) Comeback of the great imitator
Dr. Stephan Lautenschlager is a Professor of Dermatology at the University of Zurich, Switzerland. In addition, he is the Chairman of the Outpatient Clinic of Dermatology and Venereology, Triemli Hospital, also in Zurich. He has held this elected position since 2002.
Dr. Lautenschlager earned his MD at the University of Basel, Switzerland. He did his internship in Internal Medicine and Surgery at the Hospital of Davos, Switzerland, and his residency in Dermatology with the Department of Dermatology at the University Hospital of Basel. He then completed a research and clinical fellowship in Infectious Disease at the F. Hoffmann- LaRoche & Co in Switzerland, and with the Division of Infectious Disease, the University of Wisconsin Hospital in Madison, USA, respectively. Additionally, he completed a clinical medical Dermatology fellowship at the Department of Dermatology, Mayo Clinic in Rochester, USA.
Dr. Lautenschlager is a Fellow of the European Academy of Dermatology and Venereology, American Academy of Dermatology, and a member of many international societies. He is the President Elect of the Swiss Foundation against Sexually Transmitted Infections, and the Representative for Switzerland in the International Union against STIs in Europe, a position he has held since 2004.
His main clinical and research interest are clinical and epidemiological research in STIs, especially Herpes Simplex Viral infection and Syphilis. He has demonstrated leadership in the field of STI control and prevention and has widely published on these subjects in many top academic journals, as well as in the mainstream media. The results of his work have translated into practice guidelines for the treatment of people who are at risk or are affected by STIs.
For the IUSTI meeting 2017 held in Helsinki, Finland, he served as the chair of the scientific committee.